Introduction: Type 2 diabetes (T2D) is characterized by worsening pancreatic β-cell
pharmacy claims data and laboratory results, for members of a large US managed care group covering a geographically diverse population across all 50 states of the USA. The database is updated monthly and includes data with service dates from May 2000, comprising approximately 15 million annual covered lives for a total of approximately 47 million unique entries over a 10-year period.
| Patient selection
Eligible patients were adults (≥18 years of age) with T2D who had ≥1 inpatient/emergency room (ER) visit or ≥2 ambulatory medical claims (≥30 days apart) with a primary or secondary diagnosis of T2D (ICD-9-CM codes: 250.x0 or 250.x2/ICD-10-CM code: E11) during the study period. Patients categorized as long-acting insulin users were defined with ≥1 basal insulin claim for Gla-300, Gla-100, insulin detemir or insulin degludec, during the identification period (between 1 April 2015 and 31 March 2016). The index date was defined as the date of the first Gla-300 or other index basal insulin claim.
Patients were considered eligible, as switching insulin patients, if they had ≥1 claim in the 6-month baseline period prior to the index date for a different long-acting insulin, either neutral protamine Hagedorn (NPH), insulin detemir or Gla-100.
Patients were assigned to cohorts depending on whether they switched to Gla-300 or another basal insulin (Gla-100, detemir, degludec) on the index date. Included patients had continuous enrolment in the database with medical and pharmacy coverage for the 6-month baseline period and ≥3-month follow-up period after the index date; they were followed up until disenrolment, death or study end. All patients had ≥1 measurement of A1C level during the baseline period.
| Outcome assessments
The study endpoints included treatment persistence, and incidence and number of hypoglycaemic events. Patients were defined as "persistent" if they remained on the index insulin during the follow-up period without discontinuation after the index date. Patients were considered to have discontinued basal insulin if no claim was made for a refill within the expected time of medication coverage based on the metric quantity of that prescription, defined as the 90th percentile of the time between the first and second fills among patients with at least 1 refill and same metric quantity for the first fill. If no refill was claimed within that period, the date used for discontinuation was the estimated run-out data of the last claimed refill.
The incidence and number of events (adjusted for baseline confounders) of hypoglycaemia were identified by ICD-9-CM/ICD-10-CM codes for medical claims in inpatient, outpatient or ER settings during 3-and 6-month follow-up.
In a subgroup of patients who had A1C measurements at baseline and during 3-to 6-month follow-up, change in A1C from baseline to follow-up (latest available value during follow-up) was also analysed (Tables S1-S3) . 242 with A1C in 3-6 mo' follow-up (subgroup analysis)
| Statistical analyses

| RE SULTS
| Patient baseline characteristics
This analysis included 1204 patients who switched to Gla-300 and 616 patients who switched to other basal insulin analogs (Figure 1 ).
At baseline (Table 1) , patients who switched to Gla-300 compared with other basal insulins were older (mean 66.7 vs 64.3 years, respectively; P < 0.001); were more likely to be on Medicare
Advantage plans (88.4% vs 61.9%; P < 0.001); had a lower mean CCI score (3.1 vs 4.2; P < 0.001); had higher mean basal insulin DACON (41.6 vs 34.1 units/d; P = 0.001); were more likely to have used a GLP-1 RA (13.9% vs 6.3%; P < 0.001); had experienced fewer hypoglycaemic events (10.2% vs 13.5%; P = 0.038); and were less likely to have had an inpatient stay (11.8% vs 28.7%; P < 0.001) or ER visit (25.0% vs 36.9%; P < 0.001), but were more likely to have had an endocrinologist visit (29.0% vs 20.8%; P < 0.001). Mean baseline A1C levels were comparable between the 2 treatment groups.
Basal insulin use during baseline differed between patients who switched to Gla-300 and those who switched to another basal insulin, with Gla-300 switchers more likely to have been using Gla-100
(71.7% vs 35.4%; P < 0.001) or insulin detemir (25.6% vs 13.0%; P < 0.001), but less likely to have been using NPH (2.7% vs 51.6%; P < 0.001) in baseline ( Table 1 ). The percentages of other BI users after the switch were 42.1, 57.6 and 0.3 using Gla-100, detemir and degludec, respectively.
In the subgroup of patients with A1C measurements at baseline and during 3-to 6-month follow-up (492 switched to Gla-300; 242
switched to other basal insulins), baseline demographics and clinical characteristics were similar to the overall cohort.
| Treatment persistence
Fewer patients who switched to Gla-300 (20.4%) discontinued their insulin prescription compared with patients who switched to other basal insulins (36.4%) during the 6-month follow-up (Figure 2A ,B).
After adjusting for baseline confounders, Gla-300 switchers were found to be 34% less likely to discontinue basal insulin therapy dur- 
| Hypoglycaemia
Fewer Gla-300 switchers experienced hypoglycaemia at 3-and 6-month follow-up (Gla-300 switchers vs other basal insulin switchers: 3 m, 4.4% vs 8.4%, P < 0.001; 6 m, 6.0% vs 11.4%, P < 0.001).
After adjusting for baseline confounders, patients who switched to Gla-300 were less likely to experience hypoglycaemia at 3-month 
| Change in A1C
In the subgroup of patients who had A1C measurements at baseline and during 3-to 6-month follow-up, mean reductions in A1C, adjusted for baseline confounders, were modest but comparable between patients who switched to Gla-300 and other basal insulins (−0.35% vs −0.27%, respectively; adjusted mean difference: −0.08%; P = 0.578) ( Figure 4B ).
| D ISCUSS I ON
There is a growing body of RWE on glycaemic control and hypoglycaemia mirroring RCT data, but relatively few reports concerning medication persistence or discontinuation. Our data show differences in Many of the symptoms of hypoglycaemia, such as weakness, dizziness and rapid heartbeat, may be particularly challenging for elderly individuals by adding to an already increased risk for falls, cognitive impairment and other complications. 18, 19 Even among patients with T2D who initiate basal insulin, it is estimated that only 30% achieve their individual glycemic target, in part due to concerns around hypoglycaemia which may result in less timely and effective insulin titration. 20, 21 It has also been shown that hypoglycaemia leads to poor adherence and clinical outcomes, concurrent with increased healthcare resource use. [22] [23] [24] Our treatment discontinuation data for both cohorts are therefore in line with observed rates from other studies. Differences in baseline demographics and clinical characteristics may guide physicians' prescribing decisions. Although there was a statistically significant difference in age between the two groups, the actual numerical difference of only 2 years would suggest that age was an unlikely driver of treatment decisions. The lower CCI score, and lower use of inpatient and ER facilities, suggest that patients switching to Gla-300 were healthier. The presence of comorbidities is known to be a major consideration for physicians considering initiating insulin therapy; however, it is unclear how general health might affect switching in patients already using basal insulin. 17 Data from previous studies on insulin switching suggest that a higher burden of illness is a driver for switching between basal insulin analogs. 25 It may be that in our cohort, the lower level of illness in Gla-300 switchers is reflective of switching driven by the perceived advantages of the Gla-300 rather than by problems with the current basal insulin therapy. Additionally, patients switching to Gla-300 had higher baseline insulin doses.
TA B L E 1 Baseline characteristics
Patients who switched to Gla-300 had experienced fewer hypoglycaemic events at baseline than those who switched to another basal insulin. The substantially higher use of NPH insulin in the other switcher group is a possible explanation for this difference, as NPH insulin is associated with a higher rate of hypoglycaemia than Gla-100. 26, 27 It is notable that in a small retrospective study, concern regarding hypoglycaemia was one of the main reasons cited for switching to Gla-300, a result somewhat in contrast to our own data. 10 Patients switching to Gla-300 were found to be more likely to remain persistent during follow-up than those switching to other basal insulins. Although there were twice as many Gla-300 switchers, our selection criteria were not preferential for Gla-300 switchers over other switchers. Therefore, the prevalence of more Gla-300 switchers during this time period may be a function of prescriber pattern or health plan characteristics. However, we did adjust for all patient characteristics.
The previous studies have demonstrated differences in treatment persistence following switching of basal insulin, with patients switching from Gla-100 to insulin detemir being less persistent than those switching from insulin detemir to Gla-100 26, 28 ). Additionally, a positive correlation has been shown between specialist visits and F I G U R E 2 A, Prevelence of treatment discontinuation; B, discontinuation trajectory. OTH-BI, other switchers OTH-BI, other switchers. There are several other factors associated with Gla-300 treatment that may predispose to better persistence, including flexibility of injection timing, single daily injections and lower injections volumes. 25 Our study reinforces data from the EDITION trial series showing that Gla-300 is associated with less hypoglycaemia than other basal insulins. [6] [7] [8] [9] Patients in this cohort who switched to Gla-300 were less likely to experience hypoglycaemia both at 3-and at 6-month followup compared with those who switched to other basal insulins. Similar results were found in a real-world study that used propensity matching to harmonize baseline characteristics between groups, controlling for baseline confounders of hypoglycaemia.
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In the subgroup analysis of patients who had A1C measurements at baseline and during 3-to 6-month follow-up, glycaemic control was similar between the two switcher groups, a result which is in line with both the Phase III EDITION trial programme and a similar study comparing patients switching to Gla-300 or other basal insulins.
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| Limitations
While 
F I G U R E 3
Hazard ratio for risk of treatment discontinuation a . a Cox regression analysis for effect of cohort adjusted for baseline confounders. *Baseline confounders with P < 0.05. LCL, lower control limit; UCL, upper control limit The study is likely to underreport hypoglycaemia, as only ICD-9-CM/ICD-10-CM codes associated with a healthcare encounter were captured. Data interpretation may also be affected by administrative diagnosis-coding errors. Also, insulin amounts are difficult to accurately capture as the number of units of insulin originally prescribed is not always the actual number of units used by the patient, for several reasons, including up-titration of insulin doses.
Despite the use of regression analysis to control for differences in baseline factors between patients, this observational retrospective database study is not able to infer causality. The follow-up period for this study was relatively short; however, the long-term comparative effectiveness of Gla-300 and other basal insulins warrants further research. Furthermore, comparison of switching to a single insulin with switching to a group of insulins makes it difficult to interpret how therapeutic differences might affect outcomes and persistence.
| CON CLUS IONS
Randomized trial data have demonstrated similar A1C values with reduced hypoglycaemia in patients previously treated with basal insulin who switched to the second-generation basal insulin analog Gla-300. Our data collected from a real-world clinical setting show that patients who switched to Gla-300 had better persistence and an associated lower risk of hypoglycaemia compared with patients who switched to other basal insulins; both treatments showed comparable glycaemic control in the subset of patients with available data. The reduced incidence and rate of hypoglycaemia experienced, particularly in the first 3 months after treatment switch, may have contributed to the improved persistence observed with Gla-300.
The successful early initiation of insulin may therefore be an important factor in the long-term successful use of insulin.
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